SG11201907701YA - Composition and method for preventing or delaying onset of myopia comprising atropine - Google Patents

Composition and method for preventing or delaying onset of myopia comprising atropine

Info

Publication number
SG11201907701YA
SG11201907701YA SG11201907701YA SG11201907701YA SG11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA
Authority
SG
Singapore
Prior art keywords
singapore
international
myopia
preventing
pct
Prior art date
Application number
SG11201907701YA
Other languages
English (en)
Inventor
Donald Tiang Hwee Tan
Audrey Chia
Roger Beuerman
Amutha Barathi Veluchamy
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of SG11201907701YA publication Critical patent/SG11201907701YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201907701YA 2017-02-21 2018-02-20 Composition and method for preventing or delaying onset of myopia comprising atropine SG11201907701YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762461723P 2017-02-21 2017-02-21
PCT/IB2018/051039 WO2018154440A1 (en) 2017-02-21 2018-02-20 Composition and method for preventing or delaying onset of myopia comprising atropine

Publications (1)

Publication Number Publication Date
SG11201907701YA true SG11201907701YA (en) 2019-09-27

Family

ID=63253608

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907701YA SG11201907701YA (en) 2017-02-21 2018-02-20 Composition and method for preventing or delaying onset of myopia comprising atropine

Country Status (10)

Country Link
US (1) US11253507B2 (ja)
EP (1) EP3585386A4 (ja)
JP (2) JP2020509085A (ja)
KR (1) KR20200007769A (ja)
CN (1) CN110545813A (ja)
AU (1) AU2018224426B2 (ja)
NZ (1) NZ756936A (ja)
PH (1) PH12019501945A1 (ja)
SG (1) SG11201907701YA (ja)
WO (1) WO2018154440A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
CN115835905A (zh) * 2020-06-02 2023-03-21 纽约市哥伦比亚大学理事会 用于用选择性组胺h1-受体拮抗剂左卡巴斯汀及其衍生物预防和治疗近视的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
CN109310687B (zh) 2016-05-25 2023-10-20 新加坡保健服务集团 含有阿托品的水性组合物

Also Published As

Publication number Publication date
WO2018154440A1 (en) 2018-08-30
CN110545813A (zh) 2019-12-06
US11253507B2 (en) 2022-02-22
AU2018224426B2 (en) 2023-05-18
JP2022046673A (ja) 2022-03-23
JP2020509085A (ja) 2020-03-26
NZ756936A (en) 2022-11-25
AU2018224426A1 (en) 2019-09-26
KR20200007769A (ko) 2020-01-22
PH12019501945A1 (en) 2020-07-06
EP3585386A1 (en) 2020-01-01
US20200138801A1 (en) 2020-05-07
EP3585386A4 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
SG11201907701YA (en) Composition and method for preventing or delaying onset of myopia comprising atropine
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201811432WA (en) Rna for cancer therapy
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804506RA (en) Systems and methods for rendering multiple levels of detail
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201805001UA (en) Method of treating influenza a
SG11201909602TA (en) Compositions and methods involving probiotic molecules
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201811329UA (en) Spheroids including biologically-relevant materials and related methods
SG11202000125TA (en) Apparatus and methods for imaging
SG11201906616VA (en) Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201910053YA (en) Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies
SG11201909568UA (en) Reprogramming of a differentiated cell to an undifferentiated cell using exosome